I am often asked by medical students, resident physicians and—especially—patients, what is rheumatology? When students ask me why I chose to be a rheumatologist, I answer that I have never been in love with pathologies, such as rheumatoid arthritis, spondyloarthritis, gout, osteoporosis, systemic lupus erythematosus or vasculitis. In fact, I chose rheumatology because I love…
The issue of the rheumatology workforce shortage is certainly vexing. Not only does it leave large segments of the population without adequate care for patients with serious rheumatic diseases, but it also increases the burden on the few rheumatologists who serve populous, underserved regions of the country. Solutions suggested in The Rheumatologist (“ACR Workforce Solutions…
Racial Disparities in Lupus Clinical Trial Participation By Saira Z. Sheikh, MD Why was this study done? Lupus disproportionately affects Black and Latino populations, particularly women in childbearing years. Clinical trials of patients with lupus can advance the development of therapeutics and access to better treatments, as well as improve health outcomes for patients. However,…
Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…
It’s easy for rheumatologists and rheumatology professionals to feel frustrated by burdensome administrative tasks, complicated insurance policies and other healthcare hurdles. Advocacy offers a way to channel those complaints into constructive action, says Belinda Birnbaum, MD.
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
With an influx of new faces in the 118th Congress, Government Affairs Committee Chair Christina Downey, MD, notes that now is a great time to establish a relationship with your member of Congress and help them understand the day-to-day of what it takes to take care of patients.